• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

突变型 Dnmt3a 和 Npm1 在克隆性造血和髓系恶性肿瘤中细胞起源依赖性的协同作用。

Cell origin-dependent cooperativity of mutant Dnmt3a and Npm1 in clonal hematopoiesis and myeloid malignancy.

机构信息

The Jackson Laboratory for Mammalian Genetics, Bar Harbor, ME.

Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY.

出版信息

Blood Adv. 2022 Jun 28;6(12):3666-3677. doi: 10.1182/bloodadvances.2022006968.

DOI:10.1182/bloodadvances.2022006968
PMID:35413095
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9631557/
Abstract

In adult acute myeloid leukemia (AML), the acquisition of driver somatic mutations may be preceded by a benign state termed clonal hematopoiesis (CH). To develop therapeutic strategies to prevent leukemia development from CH, it is important to understand the mechanisms by which CH-driving and AML-driving mutations cooperate. Here, we use mice with inducible mutant alleles common in human CH (DNMT3AR882; mouse Dnmt3aR878H) and AML (NPM1c; mouse Npm1cA). We find that Dnmt3aR878H/+ hematopoietic stem cells (HSCs), but not multipotent progenitor cell (MPP) subsets, have reduced cytokine expression and proinflammatory transcriptional signatures and a functional competitive advantage over their wild-type counterparts. Dnmt3aR878H/+ HSCs are the most potent cell type transformed by Npm1cA, generating myeloid malignancies in which few additional cooperating somatic mutation events were detected. At a molecular level, Npm1cA, in cooperation with Dnmt3aR878H, acutely increased the accessibility of a distinct set of promoters in HSCs compared with MPP cells. These promoters were enriched for cell cycling, PI3K/AKT/mTOR signaling, stem cell signatures, and targets of transcription factors, including NFAT and the chromatin binding factor HMGB1, which have been implicated in human AML. These results demonstrate cooperativity between preexisting Dnmt3aR878H and Npm1cA at the chromatin level, where specific loci altered in accessibility by Npm1cA are dependent on cell context as well as Dnmt3a mutation status. These findings have implications for biological understanding and therapeutic intervention in the transformation from CH to AML.

摘要

在成人急性髓系白血病 (AML) 中,获得驱动体细胞突变之前,可能存在一种良性状态,称为克隆性造血 (CH)。为了开发预防 CH 驱动白血病发展的治疗策略,了解 CH 驱动和 AML 驱动突变相互作用的机制非常重要。在这里,我们使用了具有人类 CH(DNMT3AR882;小鼠 Dnmt3aR878H)和 AML(NPM1c;小鼠 Npm1cA)中常见的诱导突变等位基因的小鼠。我们发现,Dnmt3aR878H/+造血干细胞 (HSCs),而不是多能祖细胞 (MPP) 亚群,其细胞因子表达和促炎转录特征减少,并且具有相对于其野生型细胞的功能竞争优势。Dnmt3aR878H/+ HSCs 是最有能力被 Npm1cA 转化的细胞类型,产生了很少检测到其他协同体细胞突变事件的髓系恶性肿瘤。在分子水平上,Npm1cA 与 Dnmt3aR878H 合作,与 MPP 细胞相比,急性增加了 HSCs 中一组独特启动子的可及性。这些启动子富含细胞周期、PI3K/AKT/mTOR 信号通路、干细胞特征以及转录因子 NFAT 和染色质结合因子 HMGB1 的靶标,这些因子已被牵连到人类 AML 中。这些结果表明,在染色质水平上,预先存在的 Dnmt3aR878H 和 Npm1cA 之间存在协同作用,Npm1cA 改变可及性的特定基因座既依赖于细胞环境,也依赖于 Dnmt3a 突变状态。这些发现对从 CH 到 AML 的转化的生物学理解和治疗干预具有重要意义。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0cfe/9631557/9857f10d8c42/advancesADV2022006968f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0cfe/9631557/5a458686ae03/advancesADV2022006968absf1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0cfe/9631557/efe4d5bbc0b2/advancesADV2022006968f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0cfe/9631557/690a648ad11b/advancesADV2022006968f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0cfe/9631557/b799e01a1b08/advancesADV2022006968f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0cfe/9631557/9857f10d8c42/advancesADV2022006968f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0cfe/9631557/5a458686ae03/advancesADV2022006968absf1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0cfe/9631557/efe4d5bbc0b2/advancesADV2022006968f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0cfe/9631557/690a648ad11b/advancesADV2022006968f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0cfe/9631557/b799e01a1b08/advancesADV2022006968f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0cfe/9631557/9857f10d8c42/advancesADV2022006968f4.jpg

相似文献

1
Cell origin-dependent cooperativity of mutant Dnmt3a and Npm1 in clonal hematopoiesis and myeloid malignancy.突变型 Dnmt3a 和 Npm1 在克隆性造血和髓系恶性肿瘤中细胞起源依赖性的协同作用。
Blood Adv. 2022 Jun 28;6(12):3666-3677. doi: 10.1182/bloodadvances.2022006968.
2
Sequentially inducible mouse models reveal that Npm1 mutation causes malignant transformation of Dnmt3a-mutant clonal hematopoiesis.序贯诱导的小鼠模型揭示 Npm1 突变导致 Dnmt3a 突变克隆性造血的恶性转化。
Leukemia. 2019 Jul;33(7):1635-1649. doi: 10.1038/s41375-018-0368-6. Epub 2019 Jan 28.
3
Hotspot DNMT3A mutations in clonal hematopoiesis and acute myeloid leukemia sensitize cells to azacytidine via viral mimicry response.热点 DNMT3A 突变在克隆性造血和急性髓系白血病中通过病毒模拟反应使细胞对阿扎胞苷敏感。
Nat Cancer. 2021 May;2(5):527-544. doi: 10.1038/s43018-021-00213-9. Epub 2021 May 25.
4
DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling.DNMT3A突变通过受损的核小体重塑促进急性髓性白血病对蒽环类药物的耐药性。
Nat Med. 2016 Dec;22(12):1488-1495. doi: 10.1038/nm.4210. Epub 2016 Nov 14.
5
Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia.急性白血病中白血病前造血干细胞的鉴定。
Nature. 2014 Feb 20;506(7488):328-33. doi: 10.1038/nature13038. Epub 2014 Feb 12.
6
Selective advantage of mutant stem cells in human clonal hematopoiesis is associated with attenuated response to inflammation and aging.在人类克隆性造血中,突变干细胞的选择优势与对炎症和衰老的反应减弱有关。
Cell Stem Cell. 2024 Aug 1;31(8):1127-1144.e17. doi: 10.1016/j.stem.2024.05.010. Epub 2024 Jun 24.
7
Prognostic impact of clonal hematopoiesis mutations at complete molecular remission in acute myeloid leukemia with NPM1 mutation.NPM1 突变的急性髓系白血病完全分子缓解时克隆性造血突变的预后影响。
J Cancer Res Clin Oncol. 2024 Oct 18;150(10):465. doi: 10.1007/s00432-024-05999-6.
8
Therapeutic targeting of preleukemia cells in a mouse model of mutant acute myeloid leukemia.在一个突变型急性髓系白血病的小鼠模型中对白血病前细胞进行治疗性靶向。
Science. 2020 Jan 31;367(6477):586-590. doi: 10.1126/science.aax5863.
9
Chronic infection drives Dnmt3a-loss-of-function clonal hematopoiesis via IFNγ signaling.慢性感染通过 IFNγ 信号通路驱动 Dnmt3a 功能丧失性克隆性造血。
Cell Stem Cell. 2021 Aug 5;28(8):1428-1442.e6. doi: 10.1016/j.stem.2021.03.002. Epub 2021 Mar 19.
10
DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia.DOT1L作为治疗DNMT3A突变型急性髓系白血病的治疗靶点。
Blood. 2016 Aug 18;128(7):971-81. doi: 10.1182/blood-2015-11-684225. Epub 2016 Jun 22.

引用本文的文献

1
Expression of Aldehyde Dehydrogenase 1A1 in Relapse-Associated Cells in Acute Myeloid Leukemia.醛脱氢酶1A1在急性髓系白血病复发相关细胞中的表达
Cells. 2025 Jul 7;14(13):1038. doi: 10.3390/cells14131038.
2
circKCNQ5 promotes the proliferation of DNA-methyltransferase 3A R882 mutated acute myeloid leukemia cells by elevating high-mobility group box 1 expression.环状KCNQ5通过提高高迁移率族蛋白盒1的表达促进DNA甲基转移酶3A R882突变的急性髓系白血病细胞的增殖。
Ann Med. 2025 Dec;57(1):2478309. doi: 10.1080/07853890.2025.2478309. Epub 2025 Mar 25.
3
Chronic myelomonocytic leukemia with NPM1 mutation or acute myeloid leukemia?

本文引用的文献

1
Simplified murine multipotent progenitor isolation scheme: Establishing a consensus approach for multipotent progenitor identification.简化的鼠多能祖细胞分离方案:建立多能祖细胞鉴定的共识方法。
Exp Hematol. 2021 Dec;104:55-63. doi: 10.1016/j.exphem.2021.09.007. Epub 2021 Oct 11.
2
Mutational synergy during leukemia induction remodels chromatin accessibility, histone modifications and three-dimensional DNA topology to alter gene expression.在白血病诱导过程中,突变协同作用重塑染色质可及性、组蛋白修饰和三维 DNA 拓扑结构,从而改变基因表达。
Nat Genet. 2021 Oct;53(10):1443-1455. doi: 10.1038/s41588-021-00925-9. Epub 2021 Sep 23.
3
伴有NPM1突变的慢性粒单核细胞白血病还是急性髓系白血病?
Oncologist. 2025 Feb 6;30(2). doi: 10.1093/oncolo/oyae246.
4
Late-onset mutation in a MYC-amplified relapsed/refractory acute myeloid leukemia patient treated with gemtuzumab ozogamicin and glasdegib.接受吉妥珠单抗奥唑米星和格拉斯吉布治疗的MYC扩增复发/难治性急性髓系白血病患者的迟发性突变
Haematologica. 2024 Nov 1;109(11):3811-3815. doi: 10.3324/haematol.2023.284922.
5
Cell of origin epigenetic priming determines susceptibility to Tet2 mutation.起源细胞的表观遗传启动决定了对 Tet2 突变的易感性。
Nat Commun. 2024 May 21;15(1):4325. doi: 10.1038/s41467-024-48508-6.
6
XPO1 inhibition displays anti-leukemia efficacy against DNMT3A-mutant acute myeloid leukemia via downregulating glutathione pathway.XPO1 抑制通过下调谷胱甘肽通路显示出针对 DNMT3A 突变型急性髓系白血病的抗白血病疗效。
Ann Hematol. 2024 Jul;103(7):2311-2322. doi: 10.1007/s00277-024-05706-y. Epub 2024 Mar 23.
7
Mechanistic target of rapamycin in regulating macrophage function in inflammatory cardiovascular diseases.雷帕霉素靶蛋白在调节炎症性心血管疾病中巨噬细胞功能中的作用机制。
J Mol Cell Cardiol. 2024 Jan;186:111-124. doi: 10.1016/j.yjmcc.2023.10.011. Epub 2023 Nov 30.
8
Noncoding rules of survival: epigenetic regulation of normal and malignant hematopoiesis.生存的非编码规则:正常和恶性造血的表观遗传调控
Front Mol Biosci. 2023 Oct 31;10:1273046. doi: 10.3389/fmolb.2023.1273046. eCollection 2023.
9
Targeting and Monitoring Acute Myeloid Leukaemia with Nucleophosmin-1 () Mutation.靶向治疗 NPM1 突变的急性髓系白血病及其监测。
Int J Mol Sci. 2023 Feb 5;24(4):3161. doi: 10.3390/ijms24043161.
10
Clonal Hematopoiesis: Role in Hematologic and Non-Hematologic Malignancies.克隆性造血:在血液系统和非血液系统恶性肿瘤中的作用
Mediterr J Hematol Infect Dis. 2022 Sep 1;14(1):e2022069. doi: 10.4084/MJHID.2022.069. eCollection 2022.
Prognostic impact of DNMT3A mutation in acute myeloid leukemia with mutated NPM1.
DNMT3A 突变对伴有突变型 NPM1 的急性髓系白血病的预后影响。
Blood Adv. 2022 Feb 8;6(3):882-890. doi: 10.1182/bloodadvances.2020004136.
4
TFEB links MYC signaling to epigenetic control of myeloid differentiation and acute myeloid leukemia.TFEB 将 MYC 信号与髓系分化和急性髓系白血病的表观遗传控制联系起来。
Blood Cancer Discov. 2021 Mar;2(2):162-185. doi: 10.1158/2643-3230.BCD-20-0029.
5
Decline in IGF1 in the bone marrow microenvironment initiates hematopoietic stem cell aging.骨髓微环境中 IGF1 的下降引发造血干细胞衰老。
Cell Stem Cell. 2021 Aug 5;28(8):1473-1482.e7. doi: 10.1016/j.stem.2021.03.017. Epub 2021 Apr 12.
6
Chronic infection drives Dnmt3a-loss-of-function clonal hematopoiesis via IFNγ signaling.慢性感染通过 IFNγ 信号通路驱动 Dnmt3a 功能丧失性克隆性造血。
Cell Stem Cell. 2021 Aug 5;28(8):1428-1442.e6. doi: 10.1016/j.stem.2021.03.002. Epub 2021 Mar 19.
7
HMGB1: an important regulator of myeloid differentiation and acute myeloid leukemia as well as a promising therapeutic target.高迁移率族蛋白 B1:髓系分化的重要调节因子和急性髓系白血病,以及有前途的治疗靶点。
J Mol Med (Berl). 2021 Jan;99(1):107-118. doi: 10.1007/s00109-020-01998-5. Epub 2020 Oct 31.
8
DNA methylation disruption reshapes the hematopoietic differentiation landscape.DNA 甲基化破坏重塑造血分化景观。
Nat Genet. 2020 Apr;52(4):378-387. doi: 10.1038/s41588-020-0595-4. Epub 2020 Mar 23.
9
Therapeutic targeting of preleukemia cells in a mouse model of mutant acute myeloid leukemia.在一个突变型急性髓系白血病的小鼠模型中对白血病前细胞进行治疗性靶向。
Science. 2020 Jan 31;367(6477):586-590. doi: 10.1126/science.aax5863.
10
The Role of Forkhead Box Proteins in Acute Myeloid Leukemia.叉头框蛋白在急性髓系白血病中的作用
Cancers (Basel). 2019 Jun 21;11(6):865. doi: 10.3390/cancers11060865.